STOK sentiment intelligence

Stoke Therapeutics (NASDAQ:STOK) Rating Increased to Strong-Buy at The Goldman Sachs Group

The Goldman Sachs Group upgraded Stoke Therapeutics (NASDAQ:STOK) to a "strong-buy" rating. Despite the upgrade, the stock fell 6.1% to $29.46, remaining below the average analyst target price of $42.00. The company reported a narrower-than-expected quarterly loss but missed reve

Tone

Positive 64/100

Event

Analyst action

Published

14 Jul 2026 11:09

Source

MarketBeat

Goldman Sachs Initiates Coverage on Stoke Therapeutics With Buy Rating, $44 Price Target

Goldman Sachs has initiated coverage on Stoke Therapeutics (STOK) with a "Buy" rating and set a price target of $44.00. This news follows Stoke Therapeutics' recent announcement of the appointment of Thomas McCauley as Chief Scientific Officer and the completion of enrollment in

Tone

Positive 76/100

Event

Analyst action

Published

14 Jul 2026 10:43

Source

marketscreener.com

Stoke Therapeutics appoints Thomas McCauley as CSO

Stoke Therapeutics Inc. (NASDAQ:STOK) has appointed Thomas McCauley, Ph.D., as its new Chief Scientific Officer. McCauley brings over 25 years of experience and will lead the company's scientific strategy and pipeline expansion, particularly for its RNA medicines platform. The co

Tone

Positive 74/100

Event

Market update

Published

13 Jul 2026 23:09

Source

Investing.com

Stoke Therapeutics Appoints Thomas McCauley as Chief Scientific Officer

Stoke Therapeutics has appointed Thomas McCauley, Ph.D., as Chief Scientific Officer to lead its scientific strategy and research organization. McCauley brings over 25 years of experience in biotechnology, including leadership roles at Omega Therapeutics and Translate Bio. He wil

Tone

Positive 75/100

Event

Market update

Published

13 Jul 2026 14:40

Source

citybiz

Stoke Therapeutics Taps Dr. Thomas McCauley as Chief Scientific Officer

Stoke Therapeutics has appointed Dr. Thomas McCauley as its new Chief Scientific Officer. Dr. McCauley brings over 25 years of experience in leading R&D teams and translating scientific discoveries into clinical programs, with a focus on genetic medicines for rare diseases. In hi

Tone

Positive 70/100

Event

Market update

Published

13 Jul 2026 13:40

Source

Contract Pharma

Goldman Sachs initiates Stoke Therapeutics stock with buy rating on Dravet therapy potential

Goldman Sachs has initiated coverage on Stoke Therapeutics (NASDAQ:STOK) with a Buy rating and a $44 price target, citing the strong potential of its lead asset, zorevunersen, for Dravet syndrome. The investment bank believes zorevunersen could be the first disease-modifying ther

Tone

Positive 72/100

Event

Analyst action

Published

13 Jul 2026 10:06

Source

Investing.com

(STOK) and the Role of Price-Sensitive Allocations

This article analyzes Stoke Therapeutics Inc. (NASDAQ: STOK), highlighting a mid-channel oscillation pattern and a strong risk-reward setup targeting a significant gain with minimal risk. It provides three AI-generated trading strategies (Position, Momentum Breakout, and Risk Hed

Tone

Positive 76/100

Event

Market update

Published

11 Jul 2026 18:26

Source

Stock Traders Daily

Can Stoke Therapeutics (STOK) Justify Its Valuation Following The Phase 3 EMPEROR Update?

Stoke Therapeutics (STOK) is under scrutiny after completing enrollment for its Phase 3 EMPEROR study, despite recent removal from Russell indices. While the stock has seen significant long-term and short-term gains, its current $32.83 price is seen as undervalued against a fair

Tone

Positive 66/100

Event

Market update

Published

10 Jul 2026 13:10

Source

Simply Wall Street

Analysts Are Bullish on Top Healthcare Stocks: Urogen Pharma (URGN), Stoke Therapeutics (STOK)

Tone

Positive 66/100

Event

Market update

Published

10 Jul 2026 10:42

Source

The Globe and Mail

Stoke Therapeutics, Inc. (NASDAQ:STOK) Receives Consensus Rating of "Moderate Buy" from Analysts

Stoke Therapeutics, Inc. (NASDAQ:STOK) has received a consensus "Moderate Buy" rating from analysts, with nine out of eleven research firms recommending the stock as a buy. The average 12-month price target is approximately $41.83, while the stock was trading at $32.83. The compa

Tone

Positive 66/100

Event

Analyst action

Published

10 Jul 2026 06:10

Source

MarketBeat

Stoke Therapeutics highlights antisense pipeline as genetic medicine interest grows

Stoke Therapeutics, a Nasdaq-listed genetic medicines company, is advancing its antisense oligonucleotide pipeline for rare diseases. The company focuses on developing RNA-based therapies designed to increase protein production to correct or compensate for underlying genetic defe

Tone

Positive 80/100

Event

Market update

Published

08 Jul 2026 17:10

Source

AD HOC NEWS

How Investors May Respond To Stoke Therapeutics (STOK) Completing Phase 3 Enrollment For Zorevunersen In Dravet Syndrome

Stoke Therapeutics (STOK) has completed Phase 3 enrollment for zorevunersen in Dravet syndrome, with plans for a rolling New Drug Application submission to the FDA in early 2027 and full data later that year. This milestone reinforces the importance of the program as a key near-t

Tone

Positive 67/100

Event

Market update

Published

07 Jul 2026 23:09

Source

Simply Wall Street

Moran Wealth Management LLC Takes $1.32 Million Position in Stoke Therapeutics, Inc. $STOK

Moran Wealth Management LLC has purchased a new position in Stoke Therapeutics (NASDAQ:STOK) during the first quarter, acquiring 40,552 shares valued at approximately $1.32 million. This move is part of several institutional adjustments in Stoke Therapeutics holdings, with other

Tone

Positive 62/100

Event

Earnings

Published

07 Jul 2026 14:42

Source

MarketBeat

Stoke Therapeutics Announces Completion of Enrollment of 162 Patients Into the Phase 3 EMPEROR Study of Zorevunersen, an Investigational Medicine for the Treatment of Dravet Syndrome

Stoke Therapeutics has completed enrollment of 162 patients in its Phase 3 EMPEROR study of zorevunersen, an investigational medicine for Dravet syndrome. The company plans to initiate a rolling New Drug Application (NDA) submission to the U.S. FDA in Q1 2027, with Phase 3 data e

Tone

Positive 70/100

Event

Regulatory and legal

Published

01 Jul 2026 07:09

Source

Business Wire

Stoke completes Phase 3 enrollment for Dravet drug study

Stoke Therapeutics has finished enrolling 162 patients in its Phase 3 EMPEROR study for zorevunersen, a potential treatment for Dravet syndrome. The company plans to initiate a rolling FDA New Drug Application submission in Q1 2027, with data from the study expected in Q3 2027. Z

Tone

Positive 72/100

Event

Market update

Published

30 Jun 2026 15:09

Source

grafa.com

Stoke Therapeutics completes enrollment of 162 patients in Phase 3 EMPEROR; Q3 2027 readout, rolling NDA in 2027

Stoke Therapeutics has completed enrollment of 162 patients for the primary analysis population in its Phase 3 EMPEROR study of zorevunersen, with approximately 50 patients reaching the 28-week primary endpoint. The company anticipates a Phase 3 data readout in Q3 2027 and plans

Tone

Positive 75/100

Event

Market update

Published

30 Jun 2026 11:41

Source

TradingView

Stoke Therapeutics (NASDAQ: STOK) completes Phase 3 Dravet trial enrollment, targets 2027 NDA

Stoke Therapeutics has completed enrollment of 162 patients for its pivotal Phase 3 EMPEROR study of zorevunersen, a potential treatment for Dravet syndrome. The company anticipates a Phase 3 data readout in Q3 2027 and plans to initiate a rolling U.S. New Drug Application (NDA)

Tone

Positive 73/100

Event

Market update

Published

30 Jun 2026 11:41

Source

Stock Titan